<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">epilepsia</journal-id><journal-title-group><journal-title xml:lang="en">Epilepsy and paroxysmal conditions</journal-title><trans-title-group xml:lang="ru"><trans-title>Эпилепсия и пароксизмальные состояния</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2077-8333</issn><issn pub-type="epub">2311-4088</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2077-8333.2017.9.3.040-046</article-id><article-id custom-type="elpub" pub-id-type="custom">epilepsia-355</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EXPERIMENTAL EPILEPTOLOGY</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЭКСПЕРИМЕНТАЛЬНАЯ ЭПИЛЕПТОЛОГИЯ</subject></subj-group></article-categories><title-group><article-title>NOVEL PYRIMIDINE DERIVATIVES WITH ANTICONVULSANT AND PSYCHOTROPIC EFFECTS</article-title><trans-title-group xml:lang="ru"><trans-title>НОВЫE ПРОИЗВОДНЫЕ ПИРИМИДИНА С ПРОТИВОСУДОРОЖНЫМИ И ПСИХОТРОПНЫМИ СВОЙСТВАМИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пароникян</surname><given-names>Р. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Paronikyan</surname><given-names>R. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к. б.н., доцент, старший научный сотрудник Института тонкой органической химии Научно-технологического центра органической и фармацевтической химии НАН РА. Адрес: пр. Азатутян, д. 26, г. Ереван, Армения, 0014</p></bio><bio xml:lang="en"><p>PhD, Associate Professor, Senior researcher, Institute of fine organic chemistry named after A. L. Mnjoyan, Scientific technological center of organic and pharmaceutical chemistry of NAS of the Republic of Armenia. Address: pr. Azatutyan, 26, Erevan, Armeniya, 0014</p></bio><email xlink:type="simple">paronikyan.ruzanna@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Институт тонкой органической химии им. А. Л. Мнджояна научно-технологического центра органической и фармацевтической химии НАН Республики Армении</institution><country>Армения</country></aff><aff xml:lang="en"><institution>The Institute of fine organic chemistry named after A. L. Mnjoyan scientific-technological center of organic and pharmaceutical chemistry of NAS of Republic of Armenia</institution><country>Armenia</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>09</day><month>11</month><year>2017</year></pub-date><volume>9</volume><issue>3</issue><fpage>39</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Paronikyan R.G., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Пароникян Р.Г.</copyright-holder><copyright-holder xml:lang="en">Paronikyan R.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epilepsia.su/jour/article/view/355">https://www.epilepsia.su/jour/article/view/355</self-uri><abstract><sec><title>Objective</title><p>Objective: to study the anticonvulsant and psychotropic effects of novel benzothienopyrimidine derivatives and rationalize their use for medical practice.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The anticonvulsant effects were studied by using the models of murine seizure induced with corazole, camphor, thiosemicarbazide, picrotoxin, or strychnine as well as the maximal electroshock. The psychotropic properties of the compounds were studied using the “open field”, “elevated crossshaped maze”, “forced swimming”, “electroshock retrograde amnesia”, or “rotating rod” models in mice and rats.</p></sec><sec><title>Results</title><p>Results. The benzothienopyrimidine derivatives showed high anticonvulsant activities, especially against the corazoleinduced seizures.</p></sec><sec><title>Conclusion</title><p>Conclusion. The tested compounds surpass the well-known clinically used anticonvulsants 3-(p-Isopropoxyphenyl)succinimide and ethosuximide. One of the tested compounds is selected and recommended for further development as an anticonvulsant with psychotropic properties.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Цель исследования – изучение противосудорожного и психотропного действия новых производных бензотиенопиримидинов, что даст возможность получения и внедрения их в медицинскую практику.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Противосудорожное действие изучали на мышах по тестам: коразоловые, камфорные, тиосемикарбазидные, пикротоксиновые, стрихниновые судороги и максимальный электрошок, а психотропные свойства соединений исследовали на моделях: «открытое поле», «приподнятый крестообразный лабиринт», «принудительное плавание», «электрошоковая ретроградная амнезия», «вращающегося стержень» у мышей и крыс.</p></sec><sec><title>Результаты</title><p>Результаты. У производных бензотиенопиримидинов выявлена высокая противосудорожная активность, особенно по тесту коразоловых судорог.</p></sec><sec><title>Заключение</title><p>Заключение. Исследуемые соединения превосходят известные, используемые в медицинской практике, препараты 3-(п-изопропоксифенил)сукцинимид и этосуксимид. Отобранное среди них соединение может найти применение как противосудорожный препарат с психотропными свойствами.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>Бензотиенопиримидины</kwd><kwd>противосудорожная</kwd><kwd>психотропная</kwd><kwd>исследовательская активность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Benzothienopyrimidines</kwd><kwd>anticonvulsant</kwd><kwd>psychotropic</kwd><kwd>searching activity</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vogel H. G., Vogel W. H. Psychotropic and neurotropic activity. In: Drug Discovery and Evaluation: Pharmacological Assays.Ed. H. E. Vogel. Springer. Berlin and N.Y. 2008; 569-874.</mixed-citation><mixed-citation xml:lang="en">Vogel H. G., Vogel W. H. Psychotropic and neurotropic activity. In: Drug  Discovery and Evaluation: Pharmacological Assays.Ed. H. E. Vogel. Springer. Berlin  and N.Y. 2008; 569-874.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Robert M. A. Hirschfeld: Guideline Watch: Practice Guideline for the Treatment of Patients With Bipolar Disorder, 2nd Edition, in American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders 2004. 2011; 82.</mixed-citation><mixed-citation xml:lang="en">Robert M. A. Hirschfeld: Guideline Watch: Practice Guideline for the Treatment of Patients With Bipolar Disorder, 2nd Edition, in American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders 2004. 2011; 82.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Shnute M. E., Brideau R. J., Collier S. A., Cudahy M. M., Hopkins T. A., Knechtel M. L, Oien N. L, Sackett R. S., Scott A., Stephan M. L., Wathen, M. W., Wriefer J. Med. Chem Lett. 2008; 18: 3856-3859.</mixed-citation><mixed-citation xml:lang="en">Shnute M. E., Brideau R. J., Collier S. A., Cudahy M. M., Hopkins T. A., Knechtel  M. L, Oien N. L, Sackett R. S., Scott A., Stephan M. L., Wathen, M. W., Wriefer J.  Med. Chem Lett. 2008; 18: 3856-3859.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gineinah M. M., Nasr M. N. A., Badr S. M. I., El-Husseiny W. M. Med. Chem. Res. 2013; 22: 3943-3942.</mixed-citation><mixed-citation xml:lang="en">Gineinah M. M., Nasr M. N. A., Badr S. M. I., El-Husseiny W. M. Med. Chem. Res.  2013; 22: 3943-3942.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang N., Deng X. K., Li F. N., Quan Z. Sh., Iranian J. Pharm. Res. 2012; 11: 799-806.</mixed-citation><mixed-citation xml:lang="en">Jiang N., Deng X. K., Li F. N., Quan Z. Sh., Iranian J. Pharm. Res. 2012; 11: 799-806.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Baraladi P. G., Cacciari B., Moro S., Spalluto G., Pastorin G., Da Ros T., Klotz K. N., Varani K., Gessi S., Borea P. A. J. Med. Chem. 2002; 45: 770-780.</mixed-citation><mixed-citation xml:lang="en">Baraladi P. G., Cacciari B., Moro S., Spalluto G., Pastorin G., Da Ros T., Klotz  K. N., Varani K., Gessi S., Borea P. A. J. Med. Chem. 2002; 45: 770-780.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Пароникян Е. Г., Норавян А. С., Акопян А. Ш., Джагацпанян И. А., Назарян И. М., Пароникян Р. Г. Химико-фармацевтический журнал. 2007; 41 (9): 14-16.</mixed-citation><mixed-citation xml:lang="en">Paronikyan E. G., Noravyan A. S., Akopyan A. Sh., Dzhagatspanyan I. A., Nazaryan  I. M., Paronikyan R. G. Khimikofarmatsevticheskii zhurnal (in Russian). 2007; 41 (9): 14-16.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Пароникян Е. Г., Акопян А. Ш., Норавян А. С., Джагацпанян И. А., Назарян И. М., Акопян А. Г. Химико-фармацевтический журнал. 2010; 44 (4): 19-21.</mixed-citation><mixed-citation xml:lang="en">Paronikyan E. G., Akopyan A. Sh., Noravyan A. S., Dzhagatspanyan I. A., Nazaryan  I. M., Akopyan A. G. Khimikofarmatsevticheskii zhurnal (in Russian). 2010; 44 (4): 19-21.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по содержанию и использованию лабораторных животных. Восьмое издание (пер. с англ. под ред. И. В. Белозерцовой, Д. В. Блинова, М. С. Красильщиковой. М.: ИРБИС. 2017; 336 с.</mixed-citation><mixed-citation xml:lang="en">Guidelines for the content and use of laboratory animals. The eighth edition (translated from English, edited by IV Belozertzova, DV Blinov, MS Krasil’shchikova  [Rukovodstvo po soderzhaniyu i ispol’zovaniyu laboratornykh zhivotnykh. Vos’moe  izdanie (per. s angl. pod red. I. V. Belozertsovoi, D. V. Blinova, M. S.  Krasil’shchikovoi (in Russian)]. Moscow: IRBIS. 2017; 336 s.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Джагацпанян И. А, Пароникян Р. Г., Назарян И. М., Акопян А Г. Медицинская наука в Армении. 2006; 4: 14-19.</mixed-citation><mixed-citation xml:lang="en">Dzhagatspanyan I. A, Paronikyan R. G., Nazaryan I. M., Akopyan A G.  Meditsinskaya nauka v Armenii. 2006; 4: 14-19.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Behavioral and Cognitive Effecte of anticonvulsant Therapy (RE 9537). Polrey statement. 1995; 96 (3): 538-540.</mixed-citation><mixed-citation xml:lang="en">Behavioral and Cognitive Effecte of anticonvulsant Therapy (RE 9537). Polrey statement. 1995; 96 (3): 538-540.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Болдырев А. И. Журнал неврологии и психиатрии. 1998; 7: 9-11.</mixed-citation><mixed-citation xml:lang="en">Boldyrev A. I. Zhurnal nevrologii i psikhiatrii (in Russian). 1998; 7: 9-11.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Pelow S., File S. E. Pharmacol. Biochem. and Behav. 1986; 24 (3): 525-529.</mixed-citation><mixed-citation xml:lang="en">Pelow S., File S. E. Pharmacol. Biochem. and Behav. 1986; 24 (3): 525-529.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Porsolt R. D. et al. Eur. J. Pharmacol. 1978; 47: 379-391.</mixed-citation><mixed-citation xml:lang="en">Porsolt R. D. et al. Eur. J. Pharmacol. 1978; 47: 379-391.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Martindal: The Complete Drug Reference. 36 edition, 2009. N.Y.: The Pharmaceutical Press. 3694 p.</mixed-citation><mixed-citation xml:lang="en">Martindal: The Complete Drug Reference. 36 edition, 2009. N.Y.: The  Pharmaceutical Press. 3694 p.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Buresh J., Bureshova O. J. compphisiol. psychol. 1963; 756: 286-272.</mixed-citation><mixed-citation xml:lang="en">Buresh J., Bureshova O. J. compphisiol. psychol. 1963; 756: 286-272.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Covanis A., Gupta A., Jeavons P. Epilepsia. 1982; 23: 693-720.</mixed-citation><mixed-citation xml:lang="en">Covanis A., Gupta A., Jeavons P. Epilepsia. 1982; 23: 693-720.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dunham N. W., Miya T. S. А note on a simple apparatus for detecting neurological deficitin rats and mice. J. Am. Pharm. Ass. Sci. Ed. 1957; 46 (3): 208-209.</mixed-citation><mixed-citation xml:lang="en">Dunham N. W., Miya T. S. A note on a simple apparatus for detecting neurological eficitin rats and mice. J. Am. Pharm. Ass. Sci. Ed. 1957; 46 (3): 208-209.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Беленький М. Л. Количественная оценка фармакологического эффекта. М. 1961; 152 с.</mixed-citation><mixed-citation xml:lang="en">Belen’kii M. L. Quantitative assessment of the pharmacological effect [Kolichestvennaya otsenka farmakologicheskogo effekta (in Russian)]. Moscow. 1961; 152 s.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
